SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
ACAD Analysis & Videos »
ACAD: Bull or Bear?
ACAD - buy (explode soon)
ACAD
|
|
|
-56.06%
in
28 days
(closed on 09/07/09)
Money train has stopped at this station, volume will soon soar, more news will come out and I'm sure Adam F. from thestreet plans to write an article about this very soon. Same thing he did for HGSI shares could go well over $10 Citi Analyst said could go to $20 Look where HGSI is at now roughly $15! The news is out now. Time to triple your money with positive results is coming. An analyst already said "there is no drug out there in this market" Get ready for an explosion! this is the great next HGSI, DNDN.....here we go! "Currently there is no therapy in the...
|
Bullish on ACAD ...
ACAD
|
|
|
-38.52%
in
165 days
Acadia Pharma (NASDAQ: ACAD) - currently trading at $2.32, market cap = $86 million On 5/11/09, ACAD provided the following update along with its quarterly financial results: Enrollment was completed in the Company's first pivotal Phase 3 trial of pimavanserin in patients with Parkinson's disease psychosis (PDP) in early May 2009. Top-line results from this trial are expected to be reported by the end of the third quarter of 2009 (3Q09). ACAD is continuing to enroll patients in the second pivotal Phase 3 trial of pimavanserin in patients with PDP. ACADIA also is continuing to conduct an ...
|
BioMedReports.com Extreme Trades: ACAD, ANPI, BSTC, RPRX, SNTS
ACAD
|
|
|
-38.26%
in
166 days
<> Below are four companies with market caps under $200 million (all financial data current as of 6/9/09 during intraday trading) which have pending FDA decisions and/or clinical trial results that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in <font> Extreme FDA and Clinical Trial Calendar Trades </font> , which are highlighted in periodic articles at BioMedReports.com. Another approach is to simply bu...
|
Acadia Primed for Partnering
ACAD
-68.16%
in
522 days
We think Acadia is now in a strong position to seek a strategic partner for pimavanserin perhaps later in 2008.
|
Bullish on ACAD ...
ACAD
|
|
|
-91.26%
in
774 days
The fundamentals for this company are huge going into future with a big bank balance as of June 30, 2007, ACADIA's cash, cash equivalents, and investment securities totaled $153.9 million and a with a great drugs pipeline thats starting to mature. in dealing with parkinson's and schizophrenia there is a possibility of opening up a huge market 1billion+ market that no one has got a grasp of yet and results so far are good.
Also out today is an upgrade up target from$18 to $28 http://biz.yahoo.com/ap/071009/acadia_pharma_mover.html?.v=1&... and that ...
|
People Bullish on ACAD
People Bearish on ACAD
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on ACAD |
Be the first to start a discussion and earn 2 points.
More Resources
|
About ACADIA Pharmaceuticals Inc.
- Answers.com
